Dec 22, 2020, 01:00 by User Not Found

Clinical Research News | The COVID-19 pandemic has accelerated the need for a new approach to how clinical trial teams work with patients. At the onslaught of the health crisis, restrictions, and heavy precautions on personal interactions brought clinical trials to a veritable standstill. This left the life sciences industry looking for alternative ways to maintain patient participation in clinical trials, primarily, as it relates to patient interaction and data collection.

Dec 21, 2020, 01:00 by User Not Found

Clinical Research News | Funding updates around the clinical research and clinical trials space including a Series C round to accelerate decentralized trials, a “digital health first” focused VC fund, more money for a healthcare ecosystem platform, an investment in prostate health at Mount Sinai, and an NIH grant for human placental stem cell research.

Dec 18, 2020, 10:27 by

Dec 18, 2020, 01:00 by User Not Found

Clinical Research News | COVID-19 deadlier than heart disease, cancer, and the flu, with in-hospital mortality rates 20.3% among inpatients. New data on baricitinib and remdesivir. Plus: NIH looks at SARS-CoV-2 infection in children, CDC uses Oracle’s EHR, Curebase launches drive-through clinical trial sites, and new vaccine trials launched.

Dec 16, 2020, 14:09 by

Dec 16, 2020, 14:09 by

Dec 16, 2020, 14:09 by

Dec 16, 2020, 14:09 by

Dec 16, 2020, 14:09 by

AMZELL B.V to initiate a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

Dec 16, 2020, 14:08 by

BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity.

Dec 16, 2020, 14:08 by

Cytel has today announced the acquisition of Purple Squirrel Economics, expanding Cytel’s distinguished real world and advanced analytics team and further growing the global reach of Cytel’s extensive Health Economics Outcomes Research (HEOR) expertise. The acquisition marks the latest step in Cytel’s commitment to continue powering pharmaceutical development through novel applications of modern data analytics, and follows the company’s recent acquisitions of both MTEK Sciences and Ingress Health in the past year. Based in the US and Canada, Purple Squirrel Economics offers strategic leadership with a global perspective by engaging a team of senior health economists, HEOR value communication writers, research analysts, and market access professionals trusted by both regulators and payers. They help companies prove product value with rigorous quantitative insights, thereby driving products towards commercial success.

Dec 16, 2020, 14:08 by

CCT Research involved in COVID-19 vaccine research expands to Utah, partnering with local physician practices to enhance trial participation.

Dec 16, 2020, 14:08 by

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module. Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and allows patients and sites to choose how they want to participate in the study — smartphone, tablet, or web. Lunexis ePRO+ allows sites and patients to have unprecedented flexibility to choose the technology option that makes the most sense for them.

Dec 16, 2020, 14:08 by

Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda®, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer

Dec 16, 2020, 14:08 by

Cerner Corporation (NASDAQ: CERN), a global health care technology company, today announced an investment in Elligo Health Research, a leading integrated research organization that enables clinical trials with nationwide community-based health care practices.

Dec 16, 2020, 14:08 by

APIS Assay Technologies has announced a master collaboration agreement with Moffitt Cancer Centre to characterise the suitability of TROLL-2 and TROLL-3 as predictive biomarkers of cancer progression with the goal to assess the role of TROLLs as markers of response to chemotherapy. The research collaboration will aim to determine the feasibility of lncRNAs as a diagnostic tool for the prediction of efficacy of treatment pathways and prognosis of treatment outcome in chemoresistant TNBCs and further analysing NSCLC and melanoma as potential diagnostic targets for the TROLL Biomarkers.

Dec 16, 2020, 14:08 by

Scottish kidney specialist named winner at Scottish Health Awards for crucial work during coronavirus outbreak.

Dec 16, 2020, 14:08 by

iCAD ProFound AI for 3D Mammography and ProFound AI Risk will be deployed to 100 percent of Solis Mammography’s installed base, a majority of which are Hologic systems. The agreement is not exclusive. The agreement underscores promise of shifting mammography from age-based screening paradigm to a risk-adjusted precision screening paradigm personalized for every woman. ProFound AI, which aids in the detection of breast cancer in 3D mammography, or digital breast tomosynthesis (DBT), became the first software of its kind to be FDA-cleared in December 2018. The technology rapidly and accurately analyzes each DBT image, or slice, and provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. *Delivers clinically proven improvements in sensitivity, specificity, time-savings and recall rates. This leads to earlier breast cancer detection and reduced rate of false positive *ProFound AI Risk is the only commercially available risk assessment solution to provide a short term vs. long term risk of developing breast cancer based solely on a screening mammogram. *ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets.

Dec 16, 2020, 14:08 by

ENPICOM BV, an innovative bioinformatics software engineering company, has announced a strategic partnership with MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, to enhance Repertoire Sequencing data management and analysis workflows. The collaboration provides a software solution within a single platform, by combining MiLaboratories's MiXCR and ENPICOM’s cloud-based IGX Platform, allows users to choose their preferred profiling solution, leverage its intuitive user interface and unique data management capabilities.

Dec 16, 2020, 14:08 by

https://news.lifesciencenewswire.com/newsroom/medovate-announces-new-agreement-with-mercury-medical-securing-100-distributor-coverage-for-safira-in-the-usa